Washington University School of Medicine in St. Louis led pediatric COVID-19 vaccine trial launched
On Oct. 6, 2021, Washington University School of Medicine announced the start of a pediatric COVID-19 vaccine clinical…
-
-
Vaccination linked reduction of over a quarter million COVID-19 cases, 100,000 hospitalizations, and 39,000 deaths among seniors
On Oct. 5, 2021, a report from the U.S. Department of Health and Human Services (HHS) showed that…
-
Moderna announced EMA authorized third dose of COVID-19 vaccine for immunocompromised individuals aged 12 years and older
On Oct. 5, 2021, Moderna announced that the European Medicines Agency (EMA) had authorized a third dose of…
-
Johnson & Johnson submitted EUA amendment to FDA to support booster of single-shot COVID-19 vaccine
On Oct. 5, 2021, Johnson & Johnson announced it had submitted data to the U.S. Food and Drug…
-
Biotechnology | COVID-19 | Diagnostics | FDA
ACON’s Flowflex COVID-19 home test received FDA EUA
On Oct. 4, 2021, ACON Laboratories announced that its Flowflex COVID-19 Antigen Home Test had been authorized for…
-
Dynavax and U.S. Department of Defense announce collaboration to develop adjuvanted plague vaccine
On Oct. 4, 2021, Dynavax Technologies and the U.S. Department of Defense (DOD) announced Dynavax has executed an…
-
Pfizer and BioNTech received CHMP positive opinion for COVID-19 vaccine booster in the European Union
On Oct. 4, 2021, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP)…
-
Merck and Ridgeback’s oral antiviral reduced risk of hospitalization or death for patients with COVID-19 in positive phase 3 study
On Oct. 1, 2021, Merck and Ridgeback Biotherapeutics announced that molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine,…
-
Labcorp received EUA for at home collection kit for combined COVID-19 and flu detection
On Oct. 1, 2021, LabCorp announced that it had received Emergency Use Authorization (EUA) from the U.S. Food…
-
Fifteen African countries hit 10% COVID-19 vaccination goal
On Sept. 30, 2021, the WHO announced that fifteen African countries – nearly a third of the continent’s…
-
Trevena announced results of TRV027 proof-of-concept study in COVID-19 patients
On Sept. 30, 2021, Trevena announced data from 30 patients enrolled in the proof-of-concept study of TRV027, the…
-
Biotechnology | Cartoons - Original | CDC | COVID-19 | Diagnostics | FDA | Infectious Disease | NIH | Therapeutics | U.S. Congress | Vaccine
COVID-19 vaccinated vs. non-vaccinated
This cartoon illustrates the various issues facing individuals across the U.S. who are vaccinated against COVID-19 verus those…
-
Biotechnology | COVID-19 | FDA | Infectious Disease | Influenza | Vaccine
Pfizer reported positive top-line results of phase 3 study exploring coadministration of Prevnar 20 With seasonal Flu vaccine
On Sept. 29, 2021, Pfizer and BioNTech positive top-line results from a Phase 3 study (B7471004) evaluating the…
-
NEJM published positive phase 3 trial resulted for REGEN-COV (casirivimab and imdevimab) to treat COVID-19
On Sept. 29, 2021, Regeneron announced that the New England Journal of Medicine (NEJM) published positive detailed results…
-
VBI Vaccines announced preclinical data and Initiation of VBI-2905 clinical trial targeting broadened immunity against COVID-19
On Sept. 29, 2021, VBI Vaccines announced positive results from multiple preclinical studies against several COVID-19 variants of…
-
Cepheid received Emergency Use Authorization For SARS-CoV-2, Flu A, Flu B and RSV combination test
On Sept. 29, 2021, Cepheid announced it had received Emergency Use Authorization from the U.S. Food & Drug…
-
Phase II/III trial showed Ronapreve (casirivimab and imdevimab) significantly reduced viral load in patients hospitalised with COVID-19
On Sept. 29, 2021, Roche confirmed positive data from the phase II/III 2066 study, investigating Ronapreveﾙ (casirivimab and…
-
AIM ImmunoTech submitted pre-IND application to FDA for phase 2 clinical studies of Ampligen as potential therapeutic for COVID-19
On Sept. 28, 2021, AIM ImmunoTech announced that is had submitted a Pre-Investigational New Drug application (Pre-IND) to…
-
University of Missouri researchers identified mutations of Delta, Delta Plus variants
On Sept. 28, 2021, the University of Missouri researcher Kamlendra Singh led a team that analyzed protein sequences…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine | WHO
Soligenix announced publication demonstrating efficacy and broad neutralizing activity of its COVID-19 Vaccine
On Sept. 28, 2021, Soligenix announced publication of pre-clinical immunogenicity studies for CiVax (heat stable COVID-19 vaccine program)…
-
Pfizer started global phase 2/3 EPIC-PEP study of novel COVID-19 oral antiviral candidate for post-exposure prophylaxis in adults
On Sept. 27, 2021, Pfizer announced the start of the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for…
-
Moderna announced supply agreement with Peru for 20 million doses of Its COVID-19 vaccine
On Sept. 24, 2021, Moderna announced a supply agreement with the government of Peru for 20 million doses…
-
Twist Bioscience single domain antibody TB202-3 showed potent binding to multiple strains of SARS-CoV-2
On Sept. 23, 2021, Twist Bioscience reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to…
-
Novavax and Serum Institute announced submission to WHO for Emergency Use Listing of COVID-19 vaccine
On Sept. 23, 2021, Novavax with its partner, Serum Institute of India, announced a regulatory submission to the…
-
Pfizer and BioNTech received first U.S. FDA Emergency Use Authorization of a COVID-19 vaccine booster
On Sept. 23, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) has authorized…
-
Tonix Pharmaceuticals expanded research collaboration to develop precision medicine techniques for COVID-19 vaccines and therapeutics
On Sept. 23, 2021, Tonix Pharmaceuticals announced it had expanded its research collaboration with Columbia University. The research…
-
OraSure received $13.6 million from BARDA to support InteliSwab COVID-19 rapid test 510(k) Clearance and CLIA Waiver
On Sept. 23, 2021, OraSure Technologies and the Biomedical Advanced Research Development Authority (BARDA) announced up to $13.6…
-
Clover Biopharmaceuticals’s vaccine using Dynavax’s CpG 1018 adjuvant met primary and secondary efficacy endpoints
On Sept. 22, 2021, Clover Biopharmaceuticals, a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates,…
-
Veklury (Remdesivir) significantly reduced risk of hospitalization in high-risk patients with COVID-19
On Sept. 22, 2021, Gilead Sciences announced positive results from a Phase 3 randomized, double-blind, placebo-controlled trial to…
-
Pfizer and BioNTech expanded U.S. collaboration to provide 500 million additional COVID-19 vaccine doses to poorest countries
On Sept. 22, 2021, Pfizer and BioNTech announced plans to expand their agreement with the U.S. government by…
